Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19).

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 8 Feb 2023

Boucau Julie, Uddin Rockib, Marino Caitlin, Regan James, Flynn James P, Choudhary Manish C, Chen Geoffrey, Stuckwisch Ashley M, Mathews Josh, Liew May Y, Singh Arshdeep, Reynolds Zahra, Iyer Surabhi L, Chamberlin Grace C, Vyas Tammy D, Vyas Jatin M, Turbett Sarah E, Li Jonathan Z, Lemieux Jacob E, Barczak Amy K, Siedner Mark J

Abstract excerpt

We enrolled 7 individuals with recurrent symptoms or antigen test conversion following nirmatrelvir-ritonavir treatment. High viral loads (median 6.1 log10 copies/mL) were detected after rebound for a median of 17 days after initial diagnosis. Three had culturable virus for up to 16 days after initial diagnosis. No known resistance-associated mutations were identified.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to COVID-19
Share to COVID-19 Drug Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Ritonavir

Source

Open in PubMed Open full text

Identifiers

PMID: 35737946
DOI: 10.1093/cid/ciac512
PMCID: PMC9384370

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Characterization of Virologic Rebound Following Nirmatrelvir-Ritonavir Treatment for Coronavirus Disease 2019 (COVID-19).PMID 35737946Read ↗

Viral Load Rebound in Placebo and Nirmatrelvir-Ritonavir Treated COVID-19 Patients is not Associated with Recurrence of Severe Disease or MutationsSemantic proximity Read ↗

Emerging SARS-CoV-2 Resistance After Antiviral Treatment.Semantic proximity Read ↗

A unifying model to explain high nirmatrelvir therapeutic efficacy against SARS-CoV-2, despite low post-exposure prophylaxis efficacy and frequent viral reboundSemantic proximity Read ↗

Rapid Relapse of Symptomatic Omicron SARS-CoV-2 Infection Following Early Suppression with Nirmatrelvir/RitonavirSemantic proximity Read ↗

Nirmatrelvir/ritonavir and molnuipiravir in the treatment of mild/moderate COVID-19: results of a real-life studySemantic proximity Read ↗

Nirmatrelvir Resistance in an Immunocompromised Patient with Persistent Coronavirus Disease 2019.Semantic proximity Read ↗

Nirmatrelvir Resistant SARS-CoV-2 Variants with High Fitness in VitroSemantic proximity Read ↗

Remdesivir-Nirmatrelvir Combination: In Vitro Activity and a Case ReportSemantic proximity Read ↗

Nirmatrelvir Resistance-de Novo E166V/L50V Mutations in an Immunocompromised Patient Treated With Prolonged Nirmatrelvir/Ritonavir Monotherapy Leading to Clinical and Virological Treatment Failure-a Case Report.Semantic proximity Read ↗

Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture systemSemantic proximity Read ↗

Remdesivir resistance in transplant recipients with persistent COVID-19Semantic proximity Read ↗

Characterization of remdesivir resistance mutations in COVID-19 patients with various immunosuppressive diseases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.